로저스 (ROG)

Rogers Corp. (ROG) Tops Q1 Earnings and Revenue Estimates

Zacks Investment Research

Can These 5 Electronics Stocks Hit Targets This Earnings Season?

Zacks Investment Research

[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19

GlobeNewswire Inc.

FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer

GlobeNewswire Inc.

Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS

GlobeNewswire Inc.

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study

GlobeNewswire Inc.

Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis

GlobeNewswire Inc.

Roche receives FDA approval for the first molecular test to screen for malaria in blood donors

GlobeNewswire Inc.

Can Mnuchin Save NYCB From Itself?

Investing.com

Is SPDR MSCI EAFE StrategicFactors ETF (QEFA) a Strong ETF Right Now?

Zacks Investment Research

Roche Annual General Meeting 2024

GlobeNewswire Inc.

Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care

GlobeNewswire Inc.

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies

GlobeNewswire Inc.

Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies

GlobeNewswire Inc.

This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk

MarketWatch

This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk

MarketWatch

This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk

MarketWatch

New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)

GlobeNewswire Inc.

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline

GlobeNewswire Inc.

European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

GlobeNewswire Inc.

Is SPDR MSCI EAFE StrategicFactors ETF (QEFA) a Strong ETF Right Now?

Zacks Investment Research

Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform

GlobeNewswire Inc.

FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results

GlobeNewswire Inc.

Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices

GlobeNewswire Inc.

New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma

GlobeNewswire Inc.

New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A

GlobeNewswire Inc.

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment

GlobeNewswire Inc.

Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

GlobeNewswire Inc.

Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

GlobeNewswire Inc.

Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics in race to rival Novo Nordisk’s Ozempic

MarketWatch

Is Invesco S&P International Developed Quality ETF (IDHQ) a Strong ETF Right Now?

Zacks Investment Research

Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics in race to rival Novo Nordisk’s Ozempic

MarketWatch

Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, including three clinical stage assets with best-in-class potential in obesity and diabetes

GlobeNewswire Inc.

Roche expands hepatitis diagnostics portfolio to help clinicians diagnose and monitor patients with acute or chronic hepatitis B infection

GlobeNewswire Inc.

Roche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List

GlobeNewswire Inc.

Roche’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types

GlobeNewswire Inc.